Clinical Trial

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Study acronym: CAPT-HN
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
This research study is for people who have head and neck cancer that has come back or spread to other places in the body.
Protocol Amendment History 2 changes
notable Trial sites expanded: 4 -> 8 locations 2026-08-12
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-04-10
Trial Details
NCT Number NCT07062354
Lead Sponsor SWOG Cancer Research Network
Collaborators: Janssen Medical Affairs, SWOG Clinical Trials Partnerships, LLC
Conditions Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma
Enrollment 50 participants
Start Date 2026-03-25
Primary Completion 2028-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-11